Eyegate Pharmaceuticals (NASDAQ: EYEG) and Sanofi (NYSE:SNY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
This is a breakdown of recent recommendations for Eyegate Pharmaceuticals and Sanofi, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eyegate Pharmaceuticals presently has a consensus price target of $7.33, suggesting a potential upside of 532.18%. Sanofi has a consensus price target of $53.50, suggesting a potential upside of 8.96%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Eyegate Pharmaceuticals is more favorable than Sanofi.
This table compares Eyegate Pharmaceuticals and Sanofi’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.2%. Eyegate Pharmaceuticals does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend.
Volatility and Risk
Eyegate Pharmaceuticals has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Earnings and Valuation
This table compares Eyegate Pharmaceuticals and Sanofi’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Eyegate Pharmaceuticals||$767,481.00||26.00||-$13.31 million||($1.30)||-0.89|
|Sanofi||$43.43 billion||2.84||$13.03 billion||$3.92||12.53|
Sanofi has higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.3% of Sanofi shares are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.